Provider acceptability of Sayana® Press: results from community health workers and clinic-based providers in Uganda and Senegal

Operational assessments of Sayana® Press provision in Senegal and Uganda

“…This operational assessment leveraged acceptability studies conducted by FHI 360 in Senegal and Uganda [3,4] and Johns Hopkins Bloomberg School of Public Health with the Rakai Health Sciences Project in Uganda [5] by targeting the same clinics and community-based distribution programs that participated in those studies 3 and asking a sample of providers to reflect on their experience managing and administering SP. We conducted 58 semistructured interviews with both clinic providers who managed SP logistics in the clinic setting and CHWs who managed SP in the community.…”

“…However, given the nonrandom selection of participants and the small sample size, this study is purely a descriptive assessment; we do not test any specific hypotheses or test for statistical significance. 3 Refer to these studies for general information of study site and participant selection, and specific study procedures. 4 The clinics participating in the JHU/RHSP study do not have affiliated CHWs, only clinic-based providers.…”

“…2 While other studies establish the acceptability of SP [3][4][5], this study examines SP provision from a service delivery standpoint, assessing the extent to which the Uniject system with a subcutaneous needle simplifies the logistics of managing and administering injectable contraception, thereby easing concerns about task shifting to CHWs. Uniject has been studied in the context of vaccine programs (tetanus toxoid) and safe motherhood and child survival programs (oxytocin and hepatitis B), but this is only the second study to examine the Uniject delivery system in the context of a family planning program [6][7][8].…”

Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

“…They administered nearly 500,000 doses, 44% of which went to women under age 25 [12]. Women [13, 14] and health workers [15] have expressed preferences for DMPA-SC over DMPA-IM. Studies have documented interest in self-injection [16, 17] and feasibility has been assessed in Senegal, Uganda, Malawi, and elsewhere [12, 18–23].…”

Applying emerging science to contraception research: implications for the clinic

“…It is also cleared more rapidly that the higher dose formulation. In addition, development of a self-injectable system, Uniject Ò , may considerably improve the method if it becomes a user-controlled self-injectable and requires less trained providers [85]. Research is ongoing to use new molecules and new technologies for the development of a longer acting injectable with improved tolerability.…”